Drug intelligence / Profile preview

FL923

Development stage
Preclinical
Lead developer
Canget BioTekpharma
Modality
Small Molecules
01

Overview

FL923 is a preclinical small molecule anticancer agent being developed by Canget BioTekpharma as a backup compound to their lead candidate, FL118. It shares a similar mechanism of action with FL118, a camptothecin-derived molecule, by targeting and degrading the multifunctional oncogenic protein DDX5 (p68). FL923 also inhibits several key anti-apoptotic proteins, specifically survivin, Mcl-1, XIAP, and cIAP2, and is reported to target mutant KRAS (mKras). The drug is primarily positioned for the treatment of pancreatic cancer, aiming to overcome resistance mechanisms associated with these survival pathways.

02

Targets

XIAP (Baculoviral IAP repeat-containing protein 4)DDX5 (Phosphorylated-p68 RNA helicase)BIRC5 (Survivin)DDR (DNA damage response)MDM4 (Mouse double minute X homolog)MCL1 (Myeloid cell leukemia sequence 1)MYC (MYC proto-oncogene protein)

Beyond the preview

Go deeper on FL923.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL923.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call